Brokerage firm SunTrust Robinson Humphrey Downgrades its rating on INC Research Holdings Inc(INCR). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by the stock financial advisor at SunTrust Robinson Humphrey was issued on Mar 20, 2017 in a research report to their Investors and Clients.
INC Research Holdings Inc (INCR) made into the market gainers list on Wednesdays trading session with the shares advancing 1.25% or 0.55 points. Due to strong positive momentum, the stock ended at $44.45, which is also near the day’s high of $44.5. The stock began the session at $44.5 and the volume stood at 8,39,610 shares. The 52-week high of the shares is $57.11 and the 52 week low is $36.7. The company has a current market capitalization of $2,400 M and it has 5,40,01,001 shares in outstanding.
INC Research Holdings Inc(INCR) last announced its earnings results on Feb 28, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $262.979M. Analysts had an estimated revenue of $269.000M. Earnings per share were $0.67. Analysts had estimated an EPS of $0.67.
Several Insider Transactions has been reported to the SEC. On Mar 6, 2017, Alistair Macdonald (Chief Executive Officer) sold 8,828 shares at $45.00 per share price.Also, On Jan 23, 2017, Gregory S Rush (Executive VP and CFO) sold 2,907 shares at $50.58 per share price.On Jan 23, 2017, Christopher L Gaenzle (CAO, GC & Sec) sold 1,186 shares at $50.09 per share price, according to the Form-4 filing with the securities and exchange commission.
INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.